Lytix Biopharma (LYTIX) DNB Nordic Healthcare Conference Presentation summary

Company overview and technology

• Focuses on local tumor cell destruction and immune system activation to fight cancer.

• Technology is a hybrid of improved chemotherapy and modern immunotherapy, based on molecules from nature's defense system.

• Lead product LTX-315 is in advanced clinical development, with LTX-401 in preclinical stage.

• Direct intratumoral injection kills both resistant and non-resistant cancer cells and stimulates immune response against non-injected tumors.

Clinical progress and results

• Robust portfolio with three ongoing phase II studies and strong phase II results in basal cell carcinoma (BCC).

• LTX-315 achieved a 97% overall response rate and 51% complete tumor elimination in BCC patients.

• Disease control observed in 40% of late-stage melanoma patients, with stabilization up to 20 months.

• Clinical strategy includes monotherapy for skin cancer and combination therapy for early-stage cancers.

Market opportunity and positioning

• Targets large and growing markets: BCC, melanoma, and deep-seated cancers, with projected multi-billion dollar global markets by 2030.

• Addresses unmet need by converting "cold" tumors to "hot" tumors, improving response to immunotherapy.

• US is the largest oncology market; Lytix has established presence and partnerships, including with Verrica Pharmaceuticals.

• Licensing deal with Verrica secures milestone payments and royalties for future revenue.